131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine Tumors
Frank Grünwald, Samer Ezziddin
20100201
2010 Mar 1
Semin Nucl Med
131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine Tumors
Semin Nucl Med. 2010 Mar;40(2):153-163, Frank Grünwald, Samer Ezziddin
Abstract
Abstract
Treatment with 131I-metaiodobenzylguanidine (MIBG) has been introduced to the management of neuroendocrine tumors (NET) nearly 30 years ago. It provides efficient internal radiotherapy of chromaffin tumors (neuroblastoma, pheochromocytoma, and paraganglioma), but also of carcinoid and other less frequent tumors. Although for various NET types the role of this treatment form decreased by the emergence of peptide receptor radionuclide therapy, 131I-MIBG still remains the primary radiopharmaceutical...
